A direct binding assay for the determination of a Bacteroides organism

Abstract: Antigens extracted from one or more serotypes of a Bacteroides microorganism are rapidly and sensitively detected when directly bound to a water-insoluble substrate. The bound antigens are detected by forming an immunological complex on the substrate when the antigen reacts with the appropriate antibody. The antibody-antigen complex can be detected directly or by means of a second antibody which is directed to the Bacteroides antibody. The entire assay can be carried out at room temperature in less than 15 minutes.

Description: This invention relates to a direct binding method for the determination of a Bacteroides microorganism. This invention is useful in dental research and health care. There is a continuing need in medical, dental and veterinary practices, in research and diagnostic procedures, and for rapid and accurate detection or quantification of biological or chemical substances present in biological fluids or specimens. For example, the presence of various microorganisms in human and animal tissues, fluids or cells is very important for diagnosis and effective treatment of diseases. Specific microorganisms have been implicated as markers for a number of periodontal diseases in humans and animals, such as gingivitis and periodontitis. The importance of such diseases is growing in the human population, especially as people live longer, and prevention thereof is becoming of considerable medical and commercial importance. In addition, the proper care of animals (including dental care) is a growing concern in our culture. Detection of microorganisms associated with periodontal diseases has been accomplished using culture techniques (which are generally slow), DNA probes and a number of immunological procedures, such as agglutination assays, enzyme linked immunosorbent assays (ELISA), immunofluorescence and immunoprecipitation. The immunological procedures use immunological reactions of an antigenic site of the microorganism (which may be on a component extracted therefrom) with a corresponding antibody specific thereto. The resulting immunological reaction complex can then be detected in a number of ways. The black-pigmented Bacteroides species are gram negative, anaerobic rods which are common in the etiology of various periodontal diseases, odontogenic abscesses and endodontic lesions. Such species include Bacteroides intermedius , Bacteroides gingivalis , Bacteroides forsythus and Bacteroides endodontalis . Bacteroides gingivalis is also known as Porphyromonas gingivalis or as Bacteroides(Porphyromonas) gingivalis . As defined herein, periodontal disease refers to a wide variety of diseases in humans and animals which occur in the periodontal area of the oral cavity, and includes diseases affecting the cemental surfaces of the roots of teeth, alveolar bone and the gingiva. It includes diseases that may occur at different times of human life, such as in infancy, youth, pregnancy or old age. It is also known that certain serogroups or serotypes within a bacterial species which causes periodontal disease are responsible for certain forms of those diseases. For example, it is believed by some [Nakazawa and others, Infect. Immun. , 56 (6), pp. 1647-1651, 1988] that serotype B of Bacteroides intermedius is responsible for human adolescent periodontitis, while serotypes B and C are responsible for adult periodontitis. Clinical assays specific to such bacteria in gingival crevicular fluid and subgingival dental plaque are useful in the diagnosis of periodontal disease, in evaluating the options for and the progress of periodontal treatment, and in determining the status of the patient at later dental examinations. The standard culture techniques used to identify such organisms are time consuming, expensive and require a high level of operator expertise. Such tests also may lack sufficient sensitivity for detection of low levels of organisms due to strict anaerobic conditions required during transport. The various immunoassays noted above have been developed and used with some success. Particularly useful are radioimmunoprecipitation assays and ELISA tests. US-A-4,741,999 describes the production of monoclonal antibodies to antigens of Actinobacillus actinomycetemcomitans and their use in ELISA assays. Similar assays are described for other antigens in EP-A-0 239 776 and EP-A-0 335 244. Monoclonal and polyclonal antibodies to various Bacteroides species have been prepared for similar assays [see for example Nakazawa and others, noted above and Zambon and others, J. Periodon. , 56 (Supp), pp. 32-40, 1985]. Generally, the assays of the art are slow, tedious and directed to a single organism. In many cases, the assays exhibit considerable cross-reactivity with related species, and thus have limited usefulness. In EP Application Serial No. 91200049.4, a screening assay is described for detecting the presence of any of the three microorganisms Actinobacillus actinomycetemcomitans, Bacteroides gingivalis and Bacteroides intermedius . This screening method is highly useful for practitioners so they can initially determine if a patient needs periodontal treatment. However, once screening has been done, and the results are found to be positive, it would be desirable to be able to determine which microorganisms are present so the treatment can be prescribed specifically. Such treatment could then begin early. Presently, differentiation is carried out using the tedious culture or undesirable immunological methods described above. Moreover, it would be useful to have an assay which is much more rapid, but as sensitive as known culture techniques. The problems noted above with known analytical methods are overcome using a method for the determination of a Bacteroides microorganism comprising: A. contacting a specimen suspected of containing at least one antigen extracted from a Bacteroides microorganism with a solid substrate for the Bacteroides antigen to directly bind to the substrate, B. within five minutes of the contacting, separating unbound materials from the directly bound Bacteroides antigen, and contacting the directly bound antigen with at least one antibody to the Bacteroides antigen to form an immunological complex directly bound to the substrate, and C. within five minutes of the antibody-antigen contact, separating the bound complex from uncomplexed antibody and determining the presence of the bound complex as an indication of the presence of the Bacteroides antigen in the specimen. The method of this invention is rapid, reliable and simple to use. For example, it can be carried out within 15 minutes at room temperature. Thus, the tedious culture techniques and immunological assays known in the art are avoided. It is highly reliable for detecting an antigen extracted from a Bacteroides microorganism. The present invention is carried out using a direct binding assay in which a simple solid substrate is used to "capture" extracted antigen. Antigen bound in this manner is contacted with the appropriate antibodies to form an immunological complex which can be readily detected. The present invention can be used to rapidly and sensitively detect antigens (for example, lipopolysaccharides, capsule antigens or membrane proteins) of a species of Bacteroides , for example antigens of any of B. intermedius , B. gingivalis , B. forsythus , B. endodontalis and other species known to one skilled in the art. B. intermedius and B. gingivalis are particularly detectable using the present invention. While the antigens may be detectable as part of intact cells, normally, they are extracted in a suitable manner from the whole cells present in a biological specimen. Such specimens include, but are not limited to, saliva or mucous from the throat or mouth, urine, lacrimal fluid, human or animal tissue extracts, dental plaque and gingival crevicular fluid. Generally, the organism is detected in dental plaque, saliva, or gingival crevicular fluid. Antigen extraction is suitably accomplished using physical or chemical means, such as by use of detergents (such as sodium dodecyl sulfate, sodium deoxycholate or sodium decyl sulfate) using standard procedures, as described, for example, in US-A-4,741,999, osmotic shock [see for example, Dirienzo and others, Infect. & Immun. , 47 (1), pp. 31-36, 1985], or sonic means [see for example, Zambon and others, Infect. & Immun. , 41 (1), pp. 19-27, 1983]. Antibodies used in the practice of this invention can be monoclonal or polyclonal. Monoclonal antibodies can be prepared using standard procedures, such as those described in US-A-4,741,999. Polyclonal antibodies can also be produced using standard procedures, such as those described, for example in the Zambon and others reference noted above. Generally, a mammal (such as a rabbit) is immunized one or more times with a suitable quantity of antigenic component or whole bacterial cells of the organism. After a suitable time, when the titer is acceptable, antisera is recovered from the mammal. Antibodies can be removed from the antisera and purified if desired using known procedures and stored in frozen buffered solutions until used. They can be reactive with one or more serotypes of the same microorganism. Further details of such procedures are well known in the art. If desired, the antigenic material can be removed from the original specimen, or the original specimen can be suitably diluted with water or a suitable buffer, or filtered in order to remove extraneous matter and facilitate complexation of antigen and antibody in the assay. Generally, once the antibodies are isolated, they can be stored and used in buffered solutions containing one or more suitable buffers and a preservative if desired. Preferably, they are stored in frozen form. In the buffered solutions, the pH is generally maintained at from 6 to 9, and preferably at from 6.5 to 8.5. Useful buffers include phosphate buffered saline solution, tris(hydroxymethyl)aminomethane, tricine, bicine, N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid and others readily apparent to one skilled in the art. Once antigen is extracted from the microorganism, it may be desirable in some instances, that the specimen be prefiltered to remove cellular debris or other potentially interfering materials. Prefiltering can be carried out using a suitable filtration device. Extracted antigen is contacted with a suitable solid substrate to which the antigen can become bound quickly. Useful materials include those prepared from polymers, glass, ceramics, cellulosic materials and others known to one skilled in the art. The substrate can be configured in any desired shape or form, such as beads, films, porous membranes, gels or pellets. Polymeric materials are particularly useful, and can be used after a pretreatment or coating with materials which enhance antigen binding, or used without such pretreatments or coatings. Preferred solid substrates are polymeric microporous membranes having an average pore size of from 1 to 10 µmeter, and preferably an average pore size of 5 µmeter. Such membranes can be prepared from a variety of polymeric materials which can be fashioned into a thin membrane having the desired porosity, such as polyamides, polyesters, polyethyleneimines, polycarbonates, cellulosic materials and addition polymers prepared from ethylenically unsaturated polymerizable monomers. In one embodiment, the polymeric substrate is positively charged, providing a positive zeta potential on the surface of the substrate. Zeta potential is known as the potential between the support and a fluid in contact with it, and is generally determined by measuring the voltage developed as the fluid is contacted with a support. Others techniques for measuring zeta potential are also known. Generally the cationic groups on such substrates are quaternary ammonium salts, quaternary phosphonium salts, quaternary sulfonium salts, quaternary pyridinium salts, quaternary pyrimidinium salts or quaternary imidazolium salts. The charged substrate can be composed of a positively-charged polymer, or a composite of an uncharged polymer overcoated with a charged material. Examples of useful charged microporous membranes include, but are not limited to, the Posidyne™ and Biodyne™ B microporous membranes (available from Pall Corp.). Preferred microporous membranes are prepared from polyamides, that is, long chain synthetic polymers having recurring amide groups in the polymer backbone. Generally, polyamides are copolymers of a diamine and a dicarboxylic acid, or homopolymers of a lactam and an amino acid. Representative materials include, but are not limited to, polyhexamethylene dodecanediamide (nylon 612), polyhexamethylene adipamide (nylon 66), poly-ε-caprolactam (nylon 6), polyhexamethylene sebacamide (nylon 610) and poly-7-aminoheptanoamide (nylon 7) and mixtures thereof. Further details of useful membranes and details of their preparation are found in US-A-4,340,479 and Pall Corp. trade literature brochures PSD-750a (March, 1983, pp. 1-20) and NM-900c (September, 1984, pp. 1-28). Preferred membranes are marketed by Pall Corp. as Biodyne™ A and LoProdyne™ microporous membranes. The substrates described above (and especially the microporous membranes) can be coated, if desired, with one or more surfactants in order to improve fluid flow and antigen binding. Various useful anionic, nonionic and amphoteric surfactants are described in McCutcheon's Emulsifiers and Detergents , 1986 Ed., McCutheon Division Publishing Co., Glen Rock, N.J., and include Zonyl™ FSN (DuPont), Nonidet™ P-40 (Sigma Chemical), and Fluowet™ OT (American Hoechst). The substrate described herein can be used in combination with other equipment in carrying out the assay (such as bottles, beakers, test tubes or cups). Alternatively and preferably, the substrate is a membrane which is mounted in a test device in which the assay is carried out and all fluids accommodated. Useful configurations of test devices are described, for example, in US-A-3,825,410, US-A-3,970,429, US-A-4,446,232 and EP-A-0 308 231 and EP-A-0 321 261. The latter two references describe devices that are commercially available in Surecell™ test kits (Eastman Kodak Company). Most preferably, the test device contains a microporous membrane in each of three test wells, two test wells being for positive and negative controls. The extracted antigen is bound to the membranes in the test wells for immunological complexation with the appropriate antibodies. Such test devices have a water-insoluble shell into which the test wells are situated for convenient use. Embodiments other than those described in the art noted above would be readily apparent to one skilled in the art. Almost immediately upon contact of the extracted antigen with the substrate, the antigen is directly bound thereto. By "directly" is meant that the antigen is not bound to the substrate through a linking moiety, or biological compound (such as an antibody) which is attached to the support. While some adsorption of antigen may occur, it is believed to be insignificant because the assay is carried out in insufficient time and under conditions not suitable for substantial adsorption. The antigen is preferably bound to the membrane as opposed to significant amounts of other materials, cellular components, whole blood or mucous which may be present in the test specimen. Within ten minutes, preferably within one to five minutes, and most preferably within two minutes, of the contact of antigen with the substrate, the bound antigen is contacted with one or more antibodies directed thereto so as to form an immunological complex on the substrate. Fluid and unbound materials may be removed quickly at the same time, for example by drainage through a microporous membrane. In one embodiment, the antibodies used to form the bound immunological complex on the substrate is labeled for detection of the complex. Useful labels are known in the art and include chemical and biological compounds which are directly detectable using suitable procedures and equipment, as well as compounds which can be detected through further chemical or specific binding reaction to provide a detectable species. Examples of useful labels include radioisotopes, enzymes, fluorescent compounds, chemiluminescent compounds, phosphorescent compounds, biotin or its derivatives, avidin or its derivatives, ferritin, magnetizable particles, dyes particles, gold sols, dye sols, colored Staphylococcus aureus cells and others readily apparent to one skilled in the art. Radioisotopes and enzymes are preferred labels. Labels are attached to antibody molecules using known techniques. Where the label is not directly detectable, further reagents or compounds are needed to render the reaction or specific binding product detectable. For example, if the label is biotin, a conjugate of biotin and an antibody can be reacted with avidin which is conjugated with a suitable enzyme. The appropriate substrate would be used to provide a detectable species from a resulting avidin-biotin specific binding complex. Where the label is an enzyme, such as glucose oxidase, peroxidase, urease, alkaline phosphatase or β-glucosidase, the appropriate substrates and dye-providing reagents are also needed. In a particularly preferred embodiment, the label is peroxidase, and at some point in the assay hydrogen peroxide and suitable dye-providing reagents are added to provide a detectable dye in the presence of the immunological complex. Useful dye-providing reagents include, but are not limited to, triarylimidazole leuco dyes (such as those described in US-A-4,089,747). In a preferred embodiment, a method for the determination of one or more serotypes of the microorganism B. intermedius comprises: A. extracting at least one antigen from one or more serotypes of B. intermedius present in a biological specimen, B. contacting the extracted antigen with a solid substrate for a sufficient time for the extracted antigen to directly bind to the substrate, C. within two minutes of the contacting, separating unbound materials from the bound antigen, and contacting the bound antigen with a labeled antibody to the antigen to form an immunological complex bound to the substrate, D. within five minutes of the contacting in step C, separating the labeled bound complex from uncomplexed materials, and E. determining the labeled bound complex on the substrate as a measure of the amount of one or more serotypes of B. intermedius in the specimen. This same method can be carried for the determination of one or more serotypes of B. gingivalis . In another embodiment of this invention, the a first antibody to the Bacteroides antigen is not labeled, and detection of the resulting bound immunological complex is accomplished using a second antibody (described below) which is specific to the unlabeled antibody and which is appropriately labeled. Antibodies used in the method can be supplied in a composition which can contain various proteins and surfactants which reduce the nonspecific interactions on the substrate. Useful proteins include, but are not limited to, α-casein, casein, fetal bovine serum and porcine gamma globulin. Useful surfactants include, but are not limited to, amphoteric surfactants such as those commercially available as Lonzaine™ C amphoteric surfactants, and nonionic surfactants, such as those available as Tween™ nonionic surfactants. Once an immunological complex is formed on the substrate, incubation generally at room temperature (generally 18-25°C) for up to five minutes is carried out. These are very mild incubation conditions compared to those used in the assay of other antigens by direct binding methods (see for example, US-A-4,497,899). After complex formation and incubation, the complex is washed one or more times to remove unbound materials. Generally, the wash solution has a pH of from 7 to 12 and contains one or more nonionic or cationic surfactants. A particularly useful wash solution includes a cationic surfactant (such as that sold as Emcol™ CC-9) in 3-(cyclohexylamino)-2-hydroxy-1-propanesulfonic acid buffer (pH 10). In either of the embodiments described above where either one or two antibodies are used to form labeled complex bound to the substrate, the complex is directly or indirectly detected relatively quickly after washing the bound complex, that is generally within ten minutes, and preferably within one to five minutes. If desired, detection can be hastened with incubation at a suitable temperature (such as room temperature) if the reagents warrant it. The following preparation of polyclonal antibodies is a preferred method for their preparation. The bacterial strains were supplied as viable cultures by Homer S. Reynolds (SUNY, Buffalo, School of Dentistry). Isolates were anaerobically cultured on CDC anaerobic plates (BBL Laboratories, Baltimore, Md.) supplemented with hemin (5 µg/ml) and menadione (0.5 µg/ml). The plates were then incubated for 24-48 hours at 37°C in an anaerobic chamber. Frozen stocks were prepared for each strain by harvesting the colonies with an inoculating loop, preparing a cell suspension in skim milk and freezing the suspension at -70°C. Viability of the frozen stock was tested by plating a portion of the frozen stock onto CDC anaerobic plates and incubating as described above. Once viability was determined, fresh isolates for each strain could be obtained in a similar manner. Cell suspensions were prepared by harvesting colonies with an inoculating loop, placing the loop in phosphate buffered saline solution (pH 7.5, 1 ml) and vortexing vigorously for about one minute. Concentrations of cell suspensions were determined spectrophotometrically by measuring turbidity at 620 nm. Appropriate dilutions were prepared to yield an optical density in the range of 0.1 to 1. Concentrations were determined using a 1 McFarland standard wherein OD₆₂₀ = 0.180, corresponds to about 3 x 10⁸ cells/ml. Ten New Zealand white rabbits were intravenously injected with 0.5 ml of a phosphate buffered saline solution (pH 7.3) solution of the respective immunogen containing about 5 x 10⁸ whole viable cells per ml. The injections were given following the method shown in McCarty and Lancefield (J.Exp.Med. , 102 , pp. 1-28, 1955). Two booster injections were given as follows: one week after the initial injection, each rabbit was injected again with the same amount of immunogen, and one additional week later, each rabbit was similarly injected. Beginning with the fifteenth day after the initial injection, for a total of eleven additional weeks, each rabbit was given a booster injection of 1 ml of immunogen (5 x 10⁸ cells/ml) three times per week. The booster injections were spaced out every other day over each seven day period. Samples (2 ml) of antisera (for each serotype) were collected from the rabbits at various times to determine the antibody performance at those times. For example, antisera samples were taken at three, six and nine week intervals after the initial injection of immunogen. The rabbits were then sacrificed at thirteen weeks after the initial injection and the antisera was collected (about 100 ml per rabbit). The final sera were then purified using ammonium sulfate precipitation. Saturated ammonium sulfate solution was added dropwise with stirring to each serum sample, cooled on ice until 45% saturation was achieved. After the addition, the mixture was stirred for an additional ten minutes, centrifuged and the supernatant discarded. The pellet was resuspended in a volume of phosphate buffered saline solution (pH 7.3) equal to the amount of the original sample being purified. The noted steps (addition of ammonium sulfate, centrifugation and resuspension of the pellet) were repeated. The mixture was then transferred to dialysis bags and dialyzed for about fifteen hours at 4°C with stirring against phosphate buffered saline solution (pH 7.3). About 200-10,000 times excess of dialysis buffer was used. The dialysis was repeated with fresh buffer for an additional six hours. The solutions were removed from the dialysis bags and filtered through a 0.22 µmeter filter. A portion of the filtrate was diluted in the range of 1:10 to 1:100 in phosphate buffered saline solution, and the absorbance was read at 280 nm. The antibody concentration was determined according to the formula: A₂₈₀ ÷ [1.4 x (dilution)] = antibody conc.(mg/ml) The antibody solutions were then diluted to 2-4 mg/ml with phosphate buffered saline solution (pH 7.3) and merthiolate (0.01 weight %) and stored at 4°C (for small amounts whereas large amounts were stored at -70°C). The following examples are presented to illustrate the invention. All percentages are by weight unless otherwise stated. Example 1: Direct Binding Assay for Bacteroides Intermedius This example illustrates the practice of this invention to assay for all serotypes of B. intermedius . Materials and Methods : Surecell™ test devices (Eastman Kodak Co.) were used containing 5 µm Biodyne™ A microporous membranes (Pall Corp.), coated with Zonyl™ FSN nonionic surfactant (0.05 g/m², DuPont), in the three test wells. A blocking composition comprised casein (0.5%) and merthiolate preservative (0.01%) in 3-(N-morpholino)propanesulfonic acid (0.01 molar, pH 7.5). Polyclonal antibodies directed against serotype A (ATCC 25611), serotype B (NCTC 9336) and serotype C (ATCC 49046) of B. intermedius were obtained by intravenous injection of white New Zealand rabbits using the procedure described above. IgG fractions were prepared by ammonium sulfate precipitation and stored at 4°C in phosphate buffered saline solution (0.03-0.04%). ATCC is the American Type Culture Collection (Rockville, Maryland) and NCTC is the National Culture Type Collection (London). The bacterial strains used to produce the antisera were supplied in viable cultures by Homer S. Reynolds (School of Dentistry, SUNY Buffalo). Isolates were subcultured as described above. Enzyme-antibody conjugates, directed against each serotype noted above, were prepared by covalently binding horseradish peroxidase to specific rabbit polyclonal antibodies by the procedure described by Yositake and others (Eur. J. Biochem. , 101 , 395, 1979). The conjugate composition comprised each conjugate (5 µg/ml) in the blocking composition described above. Antigens from the bacterial strains, corresponding to the serotypes noted above, were extracted using phosphate buffered saline solution (pH 7.3) for about one minute at room temperature. The wash solution comprised Emcol™ CC-9 cationic surfactant (0.75%, Witco Corp.) and merthiolate (0.01%) in 3-(cyclohexylamino)-2-hydroxy-1-propane sulfonic acid (0.05 molar). The pH of the solution was raised to pH 10 by the addition of sodium hydroxide (0.05 Normal). A dye-providing composition comprised 2-(4-hydroxy-3,5-dimethoxyphenyl)-4,5-bis(4-methoxyphenyl)imidazole (0.008%), poly(vinylpyrrolidone) (1%), sodium phosphate buffer (10 mmolar, pH 6.8), hydrogen peroxide (10 mmolar), 4 ′ -hydroxyacetanilide electron transfer agent (2 mmolar) and diethylenetriaminepentaacetic acid chelating agent (10 µmolar). Assay: The extracted antigen solutions (50 µl of each cell concentration) were added to two test wells of separate test devices and allowed to bind to the membranes in the test wells. Phosphate buffered saline solution (50 µl) was added to one test well of each device to provide negative controls. The conjugate composition (50 µl) was added to each test well and the test devices were incubated at room temperature for five minutes. The wash solution (240 µl) was then added to the top of the resulting immunological complex in each test well twice, followed by addition of the dye-providing composition (50 µl) After incubation at room temperature for two minutes, the resulting dye formed on the membrane was visually evaluated and compared to a calibrated color chart of reflectance density values, then converted to transmittance density (D T ) using the Williams-Clapper transform (J. Opt. Soc. Am. , 43 , 595, 1953). The results of the assay, shown in Table I below, indicate that this invention can be used successfully to detect all three serotypes of B. intermedius using a direct binding assay. The background of the assay (0.011 D T ) was low, and the cell concentrations tested were determinable over it. Example 2: Direct Binding Assay for Bacteroides Gingivalis This example illustrates the method of this invention to assay for all serotypes of B. gingivalis . The materials and methods used in this example were same as those for Example 1 except the polyclonal antibodies used herein were directed against serotype A (ATCC 33277), serotype B (ATCC 53978) and serotype C (ATCC 53977) of B. gingivalis , and peroxidase-labeled conjugates were similarly prepared using these antibodies. The assay was carried out using the procedure described in Example 1, and the results of the dye formation in the test devices are shown in Table II below. It is clear that this direct binding assay was useful to detect B. gingivalis serotypes as the background is relatively low, and the dye density at all cell concentrations was determinable thereover.

Claims: A method for the determination of a Bacteroides microorganism comprising: A. contacting a specimen suspected of containing at least one antigen extracted from a Bacteroides microorganism with a solid substrate for the Bacteroides antigen to directly bind to the substrate, B. within five minutes of the contacting, separating unbound materials from the directly bound Bacteroides antigen, and contacting the directly bound antigen with at least one antibody to the Bacteroides antigen to form an immunological complex directly bound to the substrate, and C. within five minutes of the antibody-antigen contact, separating the bound complex from uncomplexed antibody and determining the presence of the bound complex as an indication of the presence of the Bacteroides antigen in the specimen. The method as claimed in claim 1 for the determination of antigen extracted from either Bacteroides intermedius or Bacteroides gingivalis . The method as claimed in either of claims 1 and 2 wherein the antibody is labeled with a radioisotope. The method as claimed in either of claims 1 and 2 wherein the antibody is labeled with an enzyme, and complex determination is accomplished using a composition which provides a dye in the presence of the enzyme. The method as claimed in claim 4 wherein the enzyme is peroxidase or alkaline phosphatase. The method as claimed in either of claims 1 and 2 wherein the antibody is unlabeled, and after step B and before complex determination in step C, the complex is contacted with a labeled second antibody directed to the unlabeled antibody to form a detectable antigen-antibody-antibody immunological complex bound to the substrate. The method as claimed in any of claims 1 to 6 wherein the substrate is a microporous membrane. The method as claimed in any of claims 1 to 6 wherein the substrate includes polymeric particles having an average diameter of from 0.1 to 10 µmeter. The method as claimed in any of claims 1 to 8 wherein the substrate is mounted in a disposable test device. The method as claimed in any of claims 1 to 9 wherein the antibody is a polyclonal antibody directed to all serotypes of the Bacteroides microorganism being determined. The method as claimed in any of claims 1 to 10 for the determination of multiple antigens using antibodies specific to each antigen.

Inventors: ABRAMS CATHERINE THERESA C O E, CONTESTABLE PAUL BERNARD C O E, REYNOLDS HOMER STANLEY C O EAS, SNYDER BRIAN ANTHONY C O EASTM, ZAMBON JOSEPH JAMES C O EASTMA, ABRAMS, CATHERINE THERESA, C/O EASTMAN KODAK CO., CONTESTABLE, PAUL BERNARD, C/O EASTMAN KODAK CO., REYNOLDS, HOMER STANLEY, C/O EASTMAN KODAK CO., SNYDER, BRIAN ANTHONY, C/O EASTMAN KODAK CO., ZAMBON, JOSEPH JAMES, C/O EASTMAN KODAK CO.
Applicants: EASTMAN KODAK CO, EASTMAN KODAK COMPANY
Application year: 1991
Main classification: G01N33
IPC codes: G01N33